SAN
DIEGO, June 29, 2023 /PRNewswire/ -- Avidity
Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company
committed to delivering a new class of RNA therapeutics called
Antibody Oligonucleotide Conjugates (AOCs™), today announced that
Avidity management will be participating at the following
conference:
- TD Cowen 2nd Annual RNA Therapeutics Summit
on July 10 at
8:35 a.m. PT/11:35 a.m.
ET
A live webcast of the event, up-to-date event details and an
archived replay of the webcast, will be available on the "Events
and Presentations" page in the "Investors" section of Avidity's
website at
https://aviditybiosciences.investorroom.com/events-and-presentations.
About Avidity
Avidity Biosciences, Inc.'s mission is to profoundly improve
people's lives by delivering a new class of RNA therapeutics -
Antibody Oligonucleotide Conjugates (AOCs™). Avidity is
revolutionizing the field of RNA with its proprietary AOCs, which
are designed to combine the specificity of monoclonal antibodies
with the precision of oligonucleotide therapies to address targets
and diseases previously unreachable with existing RNA therapies.
Utilizing its proprietary AOC platform, Avidity demonstrated the
first-ever successful targeted delivery of RNA into muscle and is
leading the field with clinical development programs for three rare
muscle diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular
dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD).
Avidity is broadening the reach of AOCs with its advancing and
expanding pipeline including programs in cardiology and immunology
through internal discovery efforts and key partnerships. Avidity is
headquartered in San Diego, CA. For more information
about our AOC platform, clinical development pipeline and people,
please visit www.aviditybiosciences.com and engage with
us on LinkedIn and Twitter.
Investor Contact:
Kathleen
Gallagher
(858) 401-7900 x550
investors@aviditybio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/avidity-biosciences-to-participate-in-upcoming-investor-conference-301858642.html
SOURCE Avidity Biosciences, Inc.